Thu, January 16, 2025
Wed, January 15, 2025
[ Wed, Jan 15th 2025 ]: techUK
Tech Policy: A Year in Review 2024

AbbVie and Simcere Zaiming link to develop trispecific antibody

AbbVie, a leading biopharmaceutical company, has entered into a collaboration with Simcere Zaiming, a Chinese biotech firm, to develop a trispecific antibody aimed at treating cancer. This partnership leverages Simcere Zaiming's expertise in trispecific T cell-engaging antibodies, which are designed to simultaneously target three different antigens, potentially enhancing the effectiveness of cancer immunotherapy. The agreement includes AbbVie making an upfront payment to Simcere Zaiming, with further milestone payments and royalties on future sales if the product successfully reaches the market. This collaboration not only signifies AbbVie's commitment to expanding its oncology portfolio but also highlights the growing trend of international partnerships in the biotech industry to accelerate drug development.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody/ar-AA1xgBc4 ]